Ashley M. Hopkins, PhD; Natansh D. Modi, BPharm; Ahmad Y. Abuhelwa, PhD; et al.
open access
JAMA Oncol. 2023;9(12):1621-1626. doi:10.1001/jamaoncol.2023.3996
This quality improvement study evaluates the utility of data provided by pharmaceutical companies for a planned meta-analysis of adverse events and therapeutic outcomes in trials of recently registered anticancer medicines using individual-participant data.
-
Invited Commentary
On Enhancing Clinical Trial Data Sharing
Marc Buyse, ScD
JAMA Oncol
Stéphane Oudard, MD, PhD; Raffaele Ratta, MD; Eric Voog, MD; et al.
free access
JAMA Oncol. 2023;9(12):1629-1638. doi:10.1001/jamaoncol.2023.4255
This phase 3 randomized clinical trial assesses whether biweekly cabazitaxel, 16 mg/m2, reduces the risk of grade 3 or higher neutropenia and/or neutropenic complications compared with triweekly cabazitaxel, 25 mg/m2, in patients 65 years or older with metastatic castration-resistant prostate cancer.
Eunji Choi, PhD; Victoria Y. Ding, MS; Sophia J. Luo, BS; et al.
open access
JAMA Oncol. 2023;9(12):1640-1648. doi:10.1001/jamaoncol.2023.4447
This cohort study evaluates use of risk-based screening for lung cancer with the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 2012 prediction model to address racial and ethnic disparities in individuals with a smoking history.
-
Invited Commentary
Improving Eligibility Criteria for Lung Cancer Screening鈥擯romises, Challenges, and Unmet Needs
Lecia V. Sequist, MD, MPH; Erica T. Warner, ScD, MPH; Chi-Fu Jeffrey Yang, MD
JAMA Oncol
Shukui Qin, MD, PhD; Masatoshi Kudo, MD, PhD; Tim Meyer, MD, PhD; et al.
open access
JAMA Oncol. 2023;9(12):1651-1659. doi:10.1001/jamaoncol.2023.4003
This phase 3 randomized clinical trial evaluates the efficacy and safety of tislelizumab vs sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma.
Yongwoo David Seo, MD; Hailing Lu, MD, PhD; Graeme Black, BS; et al.
open access
JAMA Oncol. 2023;9(12):1660-1668. doi:10.1001/jamaoncol.2023.4015
This nonrandomized controlled trial of patients with advanced soft tissue sarcoma analyzed the immunomodulatory effects of intratumoral glycopyranosyl lipid A in stable-emulsion formulation with concurrent radiotherapy.
Nobuyuki Takahashi, MD; Zhonglin Hao, MD; Liza C. Villaruz, MD; et al.
free access
JAMA Oncol. 2023;9(12):1669-1677. doi:10.1001/jamaoncol.2023.4025
This randomized clinical trial compares the improvement in clinical outcomes following the administration of topotecan alone with that of berzosertib plus topotecan among patients with relapsed small cell lung cancer.
Karena D. Volesky-Avellaneda, PhD; Samantha Morais, PhD; Stephen D. Walter, PhD; et al.
free access
JAMA Oncol. 2023;9(12):1678-1687. doi:10.1001/jamaoncol.2023.4273
This meta-analysis estimates the percentage and number of incident cancers attributable to infections in the US among adults and children for the most recent year cancer incidence data were available (2017).
Andreas Peyrl, MD; Monika Chocholous, MD; Magnus Sabel, MD; et al.
open access
JAMA Oncol. 2023;9(12):1688-1695. doi:10.1001/jamaoncol.2023.4437
This nonrandomized controlled trial evaluates the activity and toxicity profile of an antiangiogenic metronomic combinatorial regimen in pediatric patients with relapsed or refractory medulloblastoma.